Literature DB >> 3054191

Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor.

S D Nimer1, R E Champlin, D W Golde.   

Abstract

Human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein hormone that stimulates the growth of hematopoietic progenitor cells and enhances the functional activity of mature myeloid effector cells. Granulocyte-macrophage colony-stimulating factor was administered to eight patients with severe aplastic anemia in an attempt to restore adequate hematopoiesis. Profound decreases in serum cholesterol concentrations were observed during GM-CSF therapy that were not dependent on changes in the patients' peripheral blood cell counts. Serum cholesterol levels decreased by an average of 37% during treatment, reaching levels of less than 4.40 mmol/L in all patients. Serum cholesterol concentrations returned to baseline in all patients after discontinuation of GM-CSF therapy. Treatment with GM-CSF prominently alters cholesterol homeostasis in vivo, although the mechanism of this effect is unknown. Our results suggest that GM-CSF may be potentially useful in the treatment of hypercholesterolemia and, possibly, in the prevention and treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3054191

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  10 in total

1.  The modulation of plasma lipids and lipoproteins during bone marrow transplantation is unrelated to exogenously administered recombinant human granulocyte-monocyte colony-stimulating factor (rHu GM-CSF).

Authors:  E J Dann; Y Friedlander; E Leitersdorf; A Nagler
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

Review 2.  Macrophages and cancer.

Authors:  P W Whitworth; C C Pak; J Esgro; E S Kleinerman; I J Fidler
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

Review 3.  G-CSF and GM-CSF in clinical trials.

Authors:  K H Antman
Journal:  Yale J Biol Med       Date:  1990 Sep-Oct

Review 4.  Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis.

Authors:  Michael J Kraakman; Dragana Dragoljevic; Helene L Kammoun; Andrew J Murphy
Journal:  Clin Transl Immunology       Date:  2016-05-20

5.  Differentiation of a cell line of human cervical argyrophil small cell carcinoma to macrophage lineage cells.

Authors:  H Ichimura; N Sakashita; T Iida; T Chisaka; H Yasuda; M Kita; S Yuasa; J Imanishi
Journal:  Jpn J Cancer Res       Date:  1999-05

6.  Biochemical Changes in Blood of Patients with Duchenne Muscular Dystrophy Treated with Granulocyte-Colony Stimulating Factor.

Authors:  Dorota Sienkiewicz; Wojciech Kułak; Grażyna Paszko-Patej; Bożena Okurowska-Zawada; Jerzy Sienkiewicz; Piotr Kułak
Journal:  Biomed Res Int       Date:  2019-03-13       Impact factor: 3.411

7.  LIPID AND LIPOPROTEIN LEVELS IN HIV-INFECTED ADULTS WITH SEPSIS COMPARED TO HEALTHY HIV- INFECTED CONTROLS.

Authors:  Faheem Seedat; Frederick Raal; Neil Martinson; Ebrahim Variava
Journal:  Afr J Infect Dis       Date:  2020-07-31

8.  Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.

Authors:  P Lissoni; F Brivio; S Pittalis; M S Perego; A Ardizzoia; O Mauri; S Barni; S Crispino; G Tancini
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

9.  Macrophage-colony-stimulating factor selectively enhances macrophage scavenger receptor expression and function.

Authors:  W J de Villiers; I P Fraser; D A Hughes; A G Doyle; S Gordon
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

10.  PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.

Authors:  Ivan H Chan; Dennis Van Hoof; Marina Abramova; Melissa Bilardello; Elliot Mar; Brett Jorgensen; Scott McCauley; Harminder Bal; Martin Oft; Peter Van Vlasselaer; John B Mumm
Journal:  PLoS One       Date:  2016-06-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.